Subject(s)
Disease Susceptibility , Hepatitis B virus , Hepatitis B, Chronic/complications , Liver Cirrhosis/etiology , Polymorphism, Single Nucleotide , Aged , Alleles , Biomarkers , Disease Progression , Female , Gene Frequency , Genetic Predisposition to Disease , Genotype , Hepatitis B, Chronic/metabolism , Hepatitis B, Chronic/virology , Humans , Liver Cirrhosis/diagnosis , Liver Function Tests , Male , Middle Aged , Vitamin D/metabolismABSTRACT
AIMS: To explore the expression level and clinical significance of decoy receptor 3 (DcR3) in patients with acute-on-chronic liver failure (ACLF). METHODS: Serum DcR3 levels were measured by enzyme-linked immunosorbent assay (ELISA) in 76 patients with ACLF and 41 non-ACLF patients with chronic liver disease. Blood routine and liver functions were accessed for their correlations with DcR3. RESULTS: Serum DcR3 in ACLF patients was significantly higher than that in non-ACLF patients. It was positively correlated with neutrophilic granulocyte, aspartate aminotransferase, prothrombin time, and international standardized ratio, but negatively correlated with platelet and serum albumin. At the early stage, the level of DcR3 was not significantly different between the survival and nonsurvival group of ACLF. However, at the late stage, DcR3 increased in nonsurvival and gradually decreased in survivals. The baseline DcR3 could not sufficiently predict the outcome of ACLF, while the change of DcR3 within the first week displayed a better predictive value than model for end-stage liver disease (MELD) score. CONCLUSIONS: DcR3 was highly expressed in patients with ACLF and correlated with several clinical indices. Dynamic change of DcR3 might predict the prognosis of ACLF.
